Interneuron Licenses Treatment For Liver Disease

Interneuron Pharmaceuticals, Inc. has exercised its option and entered into an agreement to license IP 501, an orally-administered anti-fibrotic purified phospholipid compound in Phase 3 development for the treatment and prevention of liver diseases, including alcohol and Hepatitis C-induced cirrhosis.

The license agreement gives Interneuron rights to develop and commercialise the drug in several major markets, including the United States and Japan.

In addition, the Company announced the initiation of a government-funded Phase 3 clinical trial evaluating IP 501 in Hepatitis C. IP 501 is the subject of a recently completed Phase 3 clinical trial funded by the government to evaluate the compound in alcoholic cirrhosis.

The primary endpoint of the study is reduction in the progression of cirrhosis among drug-treated pre-cirrhotic patients compared with placebo patients, as measured by serial liver biopsies.

The Company expects to receive a preliminary analysis of the data in the first quarter of this year.

In addition to this trial, IP 501 is also being studied in another government-funded, multi-centre, Phase 3 clinical trial.

This recently initiated, multi-year trial is designed to evaluate the safety and effectiveness of IP 501 in treating patients with Hepatitis C-associated cirrhosis.

Under the terms of the license agreement, the Company has acquired rights to develop and commercialise IP 501 in the United States, Canada, Japan, Korea, and, under certain circumstances, Europe and other markets.

Interneuron is responsible for all remaining clinical and regulatory development, manufacturing, and marketing of the compound.

is a biopharmaceutical company engaged in the development and commercialisation of a diversified portfolio of product candidates, including multiple compounds in late- stage clinical development.

Order Dragon Pharmaceuticals Ready for Use


Selective Estrogen Receptor Modulator
Primary Chemical Name: Clomiphene Citrate
Made by: Dragon Pharmaceutical
Pack: 1 X 100 pastilles (50 mg/tablet)

EQ 300

Injectable Anabolic Steroid
Base Component: Boldenone Undecylenate
Made by: Dragon Pharmaceuticals
Pack: 1 X 10 ml (300 mg/ml)

Suspension 100

Injectable Anabolic Steroid
Basic Chemical Name: Testosterone Suspension
Producer: Dragon Pharmaceuticals
Amount: 1 X 10 ml (100 mg/ml)

Masteron 100

Injectable Anabolic Steroid
Primary Component: Drostanolone Di-Propionate
Made by: Dragon Pharma
Package: 1 X 10 ml (100 mg/ml)

NPP 150 - Bulk Price

Administration: Injection
Principal Constituent: Nandrolone Phenylpropionate
Producer: Dragon Pharma Labs
Package: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $30.00

Masteron 200

Injectable Steroid for Muscle Growth
Primary Constituent: Drostanolone Enanthate
Produced by: Dragon Pharmaceutical
10 mL Sterile Multi-dose Vial (200 mg/mL)

Primobolan 200

Injectable Steroid for Muscle Growth
Basic Substance: Methenolone Enanthate
Branded by: Dragon Pharmaceuticals
10 mL Sterile Multi-dose Vial (200 mg/mL)

Cut Mix 150

Injectable Steroid for Muscle Growth
Mix of: Testosterone Propionate,
Drostanolone Propionate, Trenbolone Acetate
Made by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (150 mg/mL)

EQ 500

Active Constituent: Boldenone Undecylenate
Produced by: Dragon Pharma Labs
Pack: 10 mL vial (500 mg/mL)


Basal Component: Chlorodehydromethyltestosterone
Branded by: Dragon Pharma
Package: 100 pills (10 mg/pill)


Basic Chemical Name: Oxandrolone
Producer: Dragon Pharmaceuticals
Amount: 100 tablets (50 mg/tablet)

Parabolan 100

Basic Ingredient: Trenbolone Hexahydrobenzylcarbonate
Made by: Dragon Pharmaceutical
Pack: 10 mL vial (100 mg/mL)